Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

被引：4
作者：
Ahmad, Suhana [1 ]
Lambuk, Lidawani [1 ]
Ahmed, Naveed [2 ]
Mussa, Ali [3 ,4 ]
Tee, Vincent [5 ]
Idris, Ros Akmal Mohd [1 ]
Sahran, Nur Fazimah [5 ]
Chan, Yean Yean [2 ]
Hassan, Rosline [3 ]
Lee, Yeong Yeh [5 ,6 ]
Mohamud, Rohimah [1 ]
机构：
[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia
[2] Univ Sains Malaysia, Sch Med Sci, Dept Med Microbiol & Parasitol, Kubang Kerian 16150, Kelantan, Malaysia
[3] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian 16150, Kelantan, Malaysia
[4] Omdurman Islamic Univ, Dept Biol, Omdurman 14415, Sudan
[5] Univ Sains Malaysia, Sch Med Sci, Dept Internal Med, Kubang Kerian 16150, Kelantan, Malaysia
[6] Univ Sains Malaysia, Hosp Univ Sains Malaysia, GI Funct & Motil Unit, Kubang Kerian 16150, Kelantan, Malaysia
来源：
NANOMEDICINE | 2023年 / 18卷 / 24期
关键词：
chemotherapy; nanomedicine; nanoparticle; response rate survival; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; PHASE-II; CHEMOTHERAPY; RAMUCIRUMAB; COMBINATION;
D O I：
10.2217/nnm-2022-0300
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel. A systematic review and meta-analysis estimates the efficacy and safety of nab-paclitaxel in metastatic gastric cancer.
引用
收藏
页码：1733 / 1744
页数：12
相关论文
共 30 条
[1]   A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer [J].
Bando, Hideaki ;
Shimodaira, Hideki ;
Fujitani, Kazumasa ;
Takashima, Atsuo ;
Yamaguchi, Kensei ;
Nakayama, Norisuke ;
Takahashi, Takehiro ;
Oki, Eiji ;
Azuma, Mizutomo ;
Nishina, Tomohiro ;
Hironaka, Shuichi ;
Komatsu, Yoshito ;
Shitara, Kohei .
EUROPEAN JOURNAL OF CANCER, 2018, 91 :86-91
[2]   Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer [J].
Blair, Hannah A. ;
Deeks, Emma D. .
DRUGS, 2015, 75 (17) :2017-2024
[3]  
Brozek J., GRADE HDB GRADING QU
[4]   Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer [J].
Cascinu, Stefano ;
Bodoky, Gyorgy ;
Muro, Kei ;
Van Cutsem, Eric ;
Oh, Sang Cheul ;
Folprecht, Gunnar ;
Ananda, Sumitra ;
Girotto, Gustavo ;
Wainberg, Zev A. ;
Miron, Maria Luisa Limon ;
Ajani, Jaffer ;
Wei, Ran ;
Liepa, Astra M. ;
Carlesi, Roberto ;
Emig, Michael ;
Ohtsu, Atsushi .
ONCOLOGIST, 2021, 26 (03) :E414-E424
[5]   A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer [J].
Chapa-Gonzalez, Christian ;
Lopez, Karina ;
Michelle Lomeli, Kimberly ;
Alberto Roacho-Perez, Jorge ;
Stevens, Jazmin Cristina .
LIFE-BASEL, 2022, 12 (03)
[6]   Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective [J].
Dranitsaris, George ;
Yu, Bo ;
Wang, Leiping ;
Sun, Weili ;
Zhou, Yan ;
King, Jennifer ;
Kaura, Satyin ;
Zhang, Adams ;
Yuan, Peng .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (02) :205-211
[7]  
Dranitsaris George, 2009, J Oncol Pharm Pract, V15, P67, DOI 10.1177/1078155208098584
[8]   nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial [J].
Goldstein, David ;
El-Maraghi, Robert Hassan ;
Hammel, Pascal ;
Heinemann, Volker ;
Kunzmann, Volker ;
Sastre, Javier ;
Scheithauer, Werner ;
Siena, Salvatore ;
Tabernero, Josep ;
Teixeira, Luis ;
Tortora, Giampaolo ;
Van Laethem, Jean-Luc ;
Young, Rosemary ;
Penenberg, Darryl Neil ;
Lu, Brian ;
Romano, Alfredo ;
Von Hoff, Daniel D. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02)
[9]   Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer [J].
He, Ming-ming ;
Wang, Feng ;
Jin, Ying ;
Yuan, Shu-qiang ;
Ren, Chao ;
Luo, Hui-yan ;
Wang, Zhi-qiang ;
Qiu, Miao-zhen ;
Wang, Zi-xian ;
Zeng, Zhao-lei ;
Li, Yu-hong ;
Wang, Feng-hua ;
Zhang, Dong-sheng ;
Xu, Rui-hua .
CANCER SCIENCE, 2018, 109 (11) :3575-3582
[10]  
Katsaounis P., 2017, NAB PACLITAXEL 2 LIN
123